Glutamate and Addiction

1. Front Matter

   Pages i-xviii

   PDF

2. Introduction

   1. Front Matter

      Pages 1-1

      PDF

   2. Molecular Pharmacology and Physiology of Glutamate Receptors

      • Karin Borges, Raymond Dingledine

      Pages 3-21

   3. Pharmacology of Glutamate Receptors

      • Jeffrey M. Witkin, Rafal Kaminski, Michael A. Rogawski

      Pages 23-49

   4. Glutamate and Neurotoxicity

      • B. Joy Snider, Dennis W. Choi

      Pages 51-61

   5. Maturational Regulation of Glutamate Receptors and Their Role in Neuroplasticity

      • Russell M. Sanchez, Frances E. Jensen

      Pages 63-70

   6. Role of the NMDA Receptor in Neuronal Apoptosis and HIV-Associated Dementia

      • Marcus Kaul, Stuart A. Lipton

      Pages 71-79

3. Glutamate

   1. Front Matter

      Pages 81-81

      PDF

   2. Role of Glutamate and Nitric Oxide in the Acquisition and Expression of Cocaine-Induced Conditioned Increases in Locomotor Activity

      • Agu Pert, Robert M. Post, Susan R. B. Weiss

      Pages 83-106

   3. Interactions of Dopamine, Glutamate, and GABA Systems in Mediating Amphetamine- and Cocaine-Induced Stereotypy and Behavioral Sensitization

      • Ralph Karler, David K. Thai, Larry D. Calder

      Pages 107-125

   4. Addiction and Glutamate-Dependent Plasticity

      • Marina E. Wolf

      Pages 127-141

   5. Glutamate and Dopamine Interactions in the Motive Circuit

      • David A. Baker, Jennifer L. Cornish, Peter W. Kalivas

      Pages 143-156

   6. Glutamate Cascade from Metabotropic Glutamate Receptors to Gene Expression in Striatal Neurons

      • John Q. Wang, Limin Mao, Yuen-Sum Lau

      Pages 157-169

   7. Glutamate Neurotransmission in the Course of Cocaine Addiction

      • Luigi Pulvirenti

      Pages 171-181

   8. Glutamate and the Self-Administration of Psychomotor-Stimulant Drugs

      • Paul Vezina, Nobuyoshi Suto

      Pages 183-200

   9. Roles of Glutamate, Nitric Oxide, Oxidative Stress, and Apoptosis in the Neurotoxicity of Methamphetamine

      • Jean Lud Cadet

      Pages 201-210

   10. Methamphetamine Toxicity

       • Kristan B. Burrows, Bryan K. Yamamoto

       Pages 211-227

   11. Nitric Oxide-Dependent Processes in the Action of Psychostimulants

       • Yossef Itzhak, Julio L. Martin, Syed F. Ali

       Pages 229-242

   12. Effects of Novel NMDA/Glycine-Site Antagonists on the Blockade of Cocaine-Induced Behavioral Toxicity in Mice

       • Rae R. Matsumoto, Buddy Pouw

       Pages 243-259

   13. Clinical Studies Using NMDA Receptor Antagonists in Cocaine and Opioid Dependence

       • Adam Bisaga, Marian W. Fischman

       Pages 261-269

In Glutamate and Addiction, world-renowned scientific experts critically review all of the evidence for the role of glutamatergic systems in opiate, stimulant, and alcohol addiction. Using a variety of pharmacological, biochemical, genetic, and brain imaging techniques, these investigators show precisely how glutamate affects such addictions and how modifying certain elements of the glutamatergic system appear to alleviate particular components of addiction. Their survey takes in both clinical approaches using medications that influence glutamate and cutting-edge preclinical approaches that manipulate specific subtypes of glutamate receptors or specific substrates of the "glutamate cascade" to determine their roles in various addictive states.

• Opioid
• amphetamine
• cocaine
• dopamine
• drugs of abuse
• imaging techniques
• neurotoxicity
• physiology

"Illuminating, authoritative, and forward looking, Glutamate and Addiction clarifies for the first time the relationship between glutamatergic systems and addiction investigations of many of today's emerging therapeutics for addictive disorders." -Biomedicine and Pharmacotherapy

• Clinical Medical Branch, Division of Treatment Research and Development, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Bethesda, USA

  Barbara H. Herman

• Pharmacology, Integrative & Cellular Neurobiology Research Branch (PICNRB), Division of Neuroscience & Behavioral Research (DNBR), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Bethesda, USA

  Jerry Frankenheim

• Treatment Research Branch, Division of Clinical and Prevention Research, National Institute on Drug Abuse (NIAAA), National Institutes of Health (NIH), Bethesda, USA

  Raye Z. Litten

• Division of Neuropharmacological Drug Products Center for Drug Evaluation and Research, Office of Drug Evaluation I, Food and Drug Administration, Rockville, USA

  Philip H. Sheridan

• Laboratory of Molecular and Cellular Neurobiology, Division of Intramural Clinical and Biological Research, National Institute on Drug Abuse (NIAAA) National Institutes of Health (NIH), Bethesda, USA

  Forrest F. Weight

• Division of Treatment Research and Development, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Bethesda, USA

  Steven R. Zukin

Policies and ethics